These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9505081)

  • 41. Co-payments for prescription drugs and the demand for doctor visits--evidence from a natural experiment.
    Winkelmann R
    Health Econ; 2004 Nov; 13(11):1081-9. PubMed ID: 15386685
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An Analysis of the Public Financial Support Eligibility Rule for French Dependent Elders with Alzheimer's Disease.
    Rapp T; Lacey L; Ousset PJ; Cowppli-Bony P; Vellas B; Orgogozo JM
    Value Health; 2015 Jul; 18(5):553-9. PubMed ID: 26297082
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Integrated care in pain therapy: innovations and coordinated treatment offers from the "Techniker Krankenkasse"].
    Brunkhorst J; Schwarz F; Klein S
    Schmerz; 2013 Apr; 27(2):129-34. PubMed ID: 23539274
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The cost escalation of social health insurance plans in China: its implication for public policy.
    Liu X; Hsiao WC
    Soc Sci Med; 1995 Oct; 41(8):1095-101. PubMed ID: 8578332
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The cost of an HIV patient. Lack of funds for optimal treatment?].
    Stoll M; Schulte E; Claes C; Graf von der Schulenburg JM; Schmidt RE
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():72-7. PubMed ID: 11373789
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996-2003.
    Lee YC; Yang MC; Huang YT; Liu CH; Chen SB
    Pharmacoeconomics; 2006; 24(9):891-902. PubMed ID: 16942123
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Strategic Provider Behavior Under Global Budget Payment with Price Adjustment in Taiwan.
    Chen B; Fan VY
    Health Econ; 2015 Nov; 24(11):1422-36. PubMed ID: 25132007
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [What is healthy economy?].
    Pedersen KM; Alban A; Danneskiold-Samsøe B
    Ugeskr Laeger; 1989 Dec; 151(51):3464-70. PubMed ID: 2514479
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Impact of an Increase in User Costs on the Demand for Emergency Services: The Case of Portuguese Hospitals.
    Ramos P; Almeida A
    Health Econ; 2016 Nov; 25(11):1372-1388. PubMed ID: 26201936
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Cost dynamics, demographic development and medical progress].
    Breyer F
    Zentralbl Chir; 1995; 120(7):496-501. PubMed ID: 7676744
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Economics of health in South Africa: past, present and future.
    Benatar SR
    Med Law; 1989; 8(2):111-7. PubMed ID: 2516586
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Cost-effectiveness of needs-oriented discharge planning in high utilizers of mental health care].
    Puschner B; Baumgartner I; Loos S; Völker KA; Ramacher M; Sohla K; Grempler J; Becker T; Kilian R
    Psychiatr Prax; 2012 Nov; 39(8):381-7. PubMed ID: 23138329
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Per-period co-payments and the demand for health care: evidence from survey and claims data.
    Farbmacher H; Winter J
    Health Econ; 2013 Sep; 22(9):1111-23. PubMed ID: 23775670
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Demand for medical care in the urban areas of Iran: an empirical investigation.
    Kermani MS; Ghaderi H; Yousefi A
    Health Econ; 2008 Jul; 17(7):849-62. PubMed ID: 17990285
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Moral hazard and supplier-induced demand: empirical evidence in general practice.
    van Dijk CE; van den Berg B; Verheij RA; Spreeuwenberg P; Groenewegen PP; de Bakker DH
    Health Econ; 2013 Mar; 22(3):340-52. PubMed ID: 22344712
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The development of the public health system between an increasing market orientation (commercialisation) and social responsibility].
    Trabert G
    Zentralbl Chir; 2008 Feb; 133(1):39-45. PubMed ID: 18278701
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Provider payment reform in China: the case of hospital reimbursement in Hainan province.
    Yip W; Eggleston K
    Health Econ; 2001 Jun; 10(4):325-39. PubMed ID: 11400255
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of cost sharing on physician utilization under favourable conditions for supplier-induced demand.
    Van de Voorde C; Van Doorslaer E; Schokkaert E
    Health Econ; 2001 Jul; 10(5):457-71. PubMed ID: 11466806
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New estimates of elasticity of demand for healthcare in rural China.
    Zhou Z; Su Y; Gao J; Xu L; Zhang Y
    Health Policy; 2011 Dec; 103(2-3):255-65. PubMed ID: 22014842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.